Plus   Neg

Boston Scientific Gets CE Mark Approval For SYNERGY Stent - Quick Facts

Boston Scientific Corp. (BSX) said it received CE Mark approval for the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating.

The SYNERGY Stent is the latest innovation in drug-eluting stent technology from Boston Scientific. It is unique in that its proprietary PLGA polymer and everolimus drug coating dissipate by three months. This innovation has the potential to improve post-implant vessel healing and will eliminate long-term polymer exposure, a possible cause of late adverse events.

The SYNERGY Stent is supported by a rigorous clinical program builds on the EVOLVE six-month study results which demonstrated non-inferiority to the Boston Scientific PROMUS Element Stent for the primary angiographic endpoint of in-stent late loss, a proxy for efficacy. At 12 months, the SYNERGY Stent demonstrated a target lesion revascularization rate of 1.1 percent and a stent thrombosis rate of 0.0 percent.

The SYNERGY Stent will be available in a full range of sizes to select centers in Europe and other geographies by early 2013. This limited market release is expected to provide additional data to support the clinical and economic benefits of this novel bioabsorbable technology. A broad commercial launch of the SYNERGY Stent is planned for early 2014.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Meredith Corp. said Wednesday that it has decided to explore the sale of its Time, Sports Illustrated, Fortune, and Money brands. In addition, the company will cut 1,000 jobs over the next ten months as part of its plan to realize cost synergies from its acquisition of Time Inc. Further, Meredith has notified about 200 employees that their positions have been eliminated. Canadian integrated oil company Cenovus Energy Inc. said Thursday that the critical shortage of export pipeline capacity in Western Canada is having a negative impact on the Canadian oil industry and showed the urgent need for approved pipeline projects in Canada to proceed as soon as possible. The company noted that Canadian heavy oil is selling at a wide discount to West Texas Intermediate. Conagra Brands, Inc. (CAG) reported that its third-quarter adjusted earnings per share from continuing operations grew 27.1% to $0.61 from $0.48, prior year. On average, 14 analysts polled by Thomson Reuters expected the company to report profit per share of $0.56 for the quarter. Analysts' estimates typically exclude special items. Aided by a lower effective tax rate, earnings per share from continuing operations grew 112.2% to $0.87 from $0.41, a year ago.
comments powered by Disqus
Follow RTT